寿仙谷品牌怎么样 申请店铺

我要投票 寿仙谷在灵芝孢子粉行业中的票数:651 更新时间:2026-01-26
寿仙谷是哪个国家的品牌?「寿仙谷」是 浙江寿仙谷医药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人李明焱在1997期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力寿仙谷品牌出海!将品牌入驻外推网,定制寿仙谷品牌推广信息,可以显著提高寿仙谷产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

寿仙谷怎么样

寿仙谷药号始建于清宣统元年(1909年),1997年成立浙江寿仙谷医药股份有限公司,地处中国温泉养生生态产业示范区的浙江省武义县。为国家高新技术企业、中华老字号企业;全国食用菌协会、中国医药教育协会副会长单位,浙江省中药材产业协会会长单位。公司致力“打造有机国药第一品牌”,长期不懈坚持铁皮石斛、灵芝、西红花等珍稀名贵中药材的优良品种选育、生态有机栽培、中药炮制技艺和新产品的研发。“寿仙谷中药炮制技艺”被国务院认定为“国家非物质文化遗产”。公司拥有一支掌握尖端高科技、医学、药学、营养学的专家和学者组成的强大科研队伍。

目前有研发人员80人,其中高级职称12人,博士5人。本科或中级以上工程技术人员52人,研发团队成员涉及医学、药学、中药学、食品、食用菌、微生物、化学检测检验、农学、营养学、生物学、生物化学及分子生物学等专业。公司建有省级“院士专家工作站”、“浙江省珍稀植物药工程技术研究中心”、“浙江寿仙谷珍稀植物药研究院”、“铁皮石斛浙江省工程研究中心”等省级研发机构。与北京大学医学部,浙江大学药学院、浙江中医药大学、上海中医药大学、北京302医院、北京广安门医院等权威研究机构建立产、学、研联合的交流平台。为浙江省星火计划培训基地、清华大学博士生实践基地、浙江大学农业与生物技术实验基地等科研实践基地。

公司先后承担了“灵芝新品种栽培及精深加工产业化研究”、“精加工灵芝优良品种选育及栽培技术研究”、“灵芝孢子破壁新工艺研究和开发”、“铁皮石斛药材及相关产品质量标准研究”等数十项国家级、省、市重大科技项目,获十项国家发明专利,十多项成果获国家、省、市科技进步奖。其中国家科技奖二等奖1项;全国工商联科技二等奖1项;浙江省科技发明二等奖1项,科学技术奖二等奖3项、三等奖2项。公司先后培育出了拥有自主知识产权的优良香菇新品种“武香1号”,铁皮石斛新品种“仙斛1号”、“仙斛2号”、“仙斛3号”,灵芝新品种“仙芝1号”、“仙芝2号”。其中“武香1号”高温香菇新品种在全国二十多个省市推广应用,至今仍为我国高温季节香菇栽培的主栽品种。铁皮石斛新品种“仙斛1号”,“仙斛2号”经过鉴定多糖含量分别高达47.1%和58.7%,远远超过2015年国家药典规定不低于25%的标准;灵芝新品种“仙芝1号”、“仙芝2号”各项指标远高日本红芝、韩芝等目前国内主栽品种。其中“仙芝1号”是国内首个经省级以上品种审定委员会认定的灵芝新品种,并保存于中国科学院微生物研究所菌物标本馆(HMAS)。2012年5月,国家农业部首个铁皮石斛地理保护标志落户浙江寿仙谷珍稀植物药研究院。公司力争打造“有机国药第一品牌”,在远离污染、风景秀丽的源口、刘秀垄等地建立了铁皮石斛、原木赤灵芝、藏红花等名贵中药材标准化仿野生栽培基地,确保了药材纯天然无污染。其中灵芝基地同时通过了中国有机产品、欧盟有机产品双重认证,铁皮石斛基地通过中国有机产品、欧盟有机产品和中药材GAP三重认证。公司通过科技创新和实践,突破了常规“企业+农户”的生产模式,实现了从中医中药基础科学研究→优良品种选育→仿野生有机栽培→传统养生秘方研究与开发→现代中药炮制与有效成分提取工艺研究→中药临床应用一整套完善的中药产业链,实施身份证可追溯制度,建立全程质量控制体系。中药炮制、饮片、直接口服微粉,检验检测中心、万级洁净检验室通过国家食品药品监督管理局的GMP认证。中药有效成分提取、浸膏剂、胶囊剂、颗粒剂、片剂等生产线通过浙江省食品药品管理局保健食品GMP认证。公司破译唐朝御医叶法善清补养生秘方,研究开发出破壁灵芝孢子粉、铁皮枫斗灵芝浸膏、铁皮枫斗颗粒、西红花铁皮枫斗浸膏等系列产品。“寿仙谷”牌灵芝系列产品荣获“中国灵芝十大品牌”,寿仙谷牌破壁灵芝孢子粉荣获全国科技创新成果奖。“寿仙谷铁皮石斛”荣获“中国好石斛”荣誉称号。系列产品成为杭州胡庆余堂、方回春堂,北京同仁堂、白塔寺药店,广州采芝林等多家百年老字号指定产品,畅销京、沪、浙、苏并快速走向全国。

公司为“中医药-灵芝”及“中医药-铁皮石斛”国际标准领衔制定单位,也是国家铁皮枫斗质量标准制定单位。还是现行浙江省灵芝孢子粉炮制规范、浙江省鲜铁皮石斛炮制规范领衔制定单位,同时为浙江省地方标准《段木灵芝生产技术规程》、《浙江省铁皮石斛生产技术规程》的主要制订者。公司先后获评中国中药协会灵芝道地药材保护与规范化种植示范基地、铁皮石斛道地药材保护与规范化种植基地;国家有机食品生产基地;中华中医药学会、中国科学技术协会“药学科普示范中药基地”、团中央“全国青少年农业科普示范基地”。中国保健品AAA级信用企业、中国食(药)用菌AAA级信用企业;浙江省诚信企业、浙江省信用管理示范企业、浙江省铁皮石斛生产基地信用等级三A级单位;全国食用菌行业十大龙头企业,浙江省优质产地药材示范基地,浙江省现代农业园区石斛精品园(省内首家),浙江省中医药文化养生旅游示范基地(省内首家),浙江省优秀民营企业、浙江省创新型企业、金华市政府质量奖等荣誉。

Shouxiangu Pharmaceutical Co., Ltd. was founded in 1909. It is located in Wuyi County, Zhejiang Province, China's demonstration area of hot spring health preservation industry. It is a national high-tech enterprise, Chinese time-honored brand enterprise, vice chairman unit of national edible fungus Association, China Medical Education Association, and chairman unit of Zhejiang traditional Chinese Medicine Industry Association. The company is committed to "building the first brand of organic Chinese medicine", and persisting in the selection of excellent varieties, ecological organic cultivation, processing technology of traditional Chinese medicine and research and development of new products of precious Chinese medicine such as Dendrobium candidum, Ganoderma lucidum and crocus. "Shouxiangu traditional Chinese medicine processing technology" is recognized as "national intangible cultural heritage" by the State Council. The company has a strong scientific research team composed of experts and scholars who master cutting-edge high technology, medicine, pharmacy and nutrition. At present, there are 80 R & D personnel, including 12 with senior titles and 5 with doctors. There are 52 engineering and technical personnel with bachelor's degree or above, and the R & D team members include medicine, pharmacy, Chinese pharmacy, food, edible fungus, microorganism, chemical detection and inspection, agriculture, nutrition, biology, biochemistry and molecular biology. The company has provincial research and development institutions such as "academician expert workstation", "Zhejiang rare plant medicine engineering technology research center", "Zhejiang shouxiangu rare plant medicine research institute", "Dendrobium officinale Engineering Research Center of Zhejiang Province" and so on. Establish an exchange platform of production, learning and research with the medical department of Peking University, School of medicine of Zhejiang University, Zhejiang University of traditional Chinese medicine, Shanghai University of traditional Chinese medicine, Beijing 302 Hospital, Beijing Guang'anmen Hospital and other authoritative research institutions. It is the training base of Spark Program in Zhejiang Province, the doctoral practice base of Tsinghua University, the agricultural and biotechnology experiment base of Zhejiang University, etc. The company has successively undertaken dozens of national, provincial and municipal major scientific and technological projects, such as "Research on the cultivation of new varieties of Ganoderma lucidum and the industrialization of intensive processing", "Research on the selection and cultivation technology of fine varieties of refined Ganoderma lucidum", "research and development on the new technology of spore wall breaking of Ganoderma lucidum", "Research on the quality standard of Dendrobium officinale and its related products", and has won ten national invention patents and more than ten success And won the national, provincial and municipal science and technology progress award. Among them, there are 1 second prize of national science and technology award, 1 second prize of National Federation of industry and commerce, 1 second prize of Zhejiang Province Science and technology invention, 3 second prizes and 2 third prizes of science and technology award. The company has successively cultivated new varieties of mushroom "Wuxiang No.1", new varieties of Dendrobium candidum "Xianhu No.1", "Xianhu No.2", "Xianhu No.3", new varieties of Ganoderma lucidum "Xianzhi No.1" and "Xianzhi No.2" with independent intellectual property rights. Among them, "Wuxiang No. 1" high temperature Lentinus edodes is popularized and applied in more than 20 provinces and cities in China, and it is still the main variety cultivated in high temperature season in China. The polysaccharide content of new Dendrobium officinale varieties "Xianhu No.1" and "Xianhu No.2" was 47.1% and 58.7% respectively, which far exceeded the national pharmacopoeia standard of no less than 25% in 2015. The indexes of new Ganoderma lucidum varieties "Xianzhi No.1" and "Xianzhi No. Among them, "Xianzhi No. 1" is the first new variety of Ganoderma lucidum recognized by the variety examination and Approval Committee at or above the provincial level in China, and it is preserved in HMAS. In May 2012, the first geographical protection mark of Dendrobium officinale by the Ministry of agriculture of the people's Republic of China was established in Zhejiang shouxiangu rare plant medicine research institute. The company strives to build "the first brand of organic Chinese medicine", and has established standardized and imitated wild cultivation bases of Dendrobium candidum, log Ganoderma lucidum, saffron and other precious Chinese medicine in Yuankou, liuxiulong and other places far away from pollution and beautiful scenery, so as to ensure that the medicine is pure and natural without pollution. Among them, Ganoderma lucidum base has passed the dual certification of China's organic products and EU's organic products, while Dendrobium candidum base has passed the triple certification of China's organic products, EU's organic products and traditional Chinese medicine gap. Through scientific and technological innovation and practice, the company has broken through the conventional production mode of "enterprise + farmer", realized a complete set of complete TCM industry chain from the basic scientific research of TCM → selection of excellent varieties → imitating wild organic cultivation → research and development of traditional health keeping secret recipe → research on modern TCM processing and effective ingredient extraction process → clinical application of TCM, and implemented ID card traceability System, establish the whole process quality control system. Traditional Chinese medicine processing, decoction pieces, direct oral micro powder, inspection and testing center, 10000 level clean inspection room have passed the GMP certification of the State Food and drug administration. The production lines for the extraction of effective ingredients, extract, capsule, granule and tablet of traditional Chinese medicine have passed the GMP certification of health food of Zhejiang food and drug administration. The company deciphers the secret recipe of Tang Dynasty Royal doctor ye Fasan's qingbu health preservation, and researches and develops a series of products, such as broken wall ganoderma spore powder, Tiepi Fengdou ganoderma extract, Tiepi Fengdou granules, xihonghua Tiepi Fengdou extract, etc. "Shouxiangu" brand Ganoderma series products won the "top ten Chinese Ganoderma brands", and shouxiangu brand broken wall ganoderma spore powder won the national science and technology innovation achievement award. "Dendrobium officinale in Shouxian Valley" won the honorary title of "good Dendrobium in China". The series products have become the designated products of Huqingyutang and fanghuichuntang in Hangzhou, Tongrentang and Baitasi drugstores in Beijing, Caizhilin in Guangzhou and many other century old brands. They sell well in Beijing, Shanghai, Zhejiang and Jiangsu, and quickly move to the whole country. The company is the leading international standard setting unit of "Chinese Medicine - Ganoderma lucidum" and "Chinese Medicine - Dendrobium candidum". It is also the national quality standard setting unit of maple peel. At the same time, he is the main maker of Zhejiang local standards, such as the production technical regulations of Ganoderma Duanmu and the production technical regulations of Dendrobium candidum. The company has successively won the awards of Ganoderma lucidum genuine medicine protection and standardized planting demonstration base, Dendrobium candidum genuine medicine protection and standardized planting base, national organic food production base, China Society of traditional Chinese medicine, China Association of science and technology "pharmaceutical popular science demonstration Chinese medicine base" and "National Youth agricultural popular science demonstration base" of the Communist Youth League Central Committee. AAA credit enterprise of Chinese health products, AAA credit enterprise of Chinese food (Medicine) fungus; Credit Grade 3A unit of Zhejiang credit enterprise, Zhejiang credit management demonstration enterprise, and Zhejiang Dendrobium officinale production base; top 10 leading enterprises of edible fungus industry in China, Zhejiang high-quality origin medicine demonstration base, and Zhejiang modern agricultural park Dendrobium boutique Park (the first in Zhejiang Province), Zhejiang traditional Chinese medicine cultural health tourism demonstration base (the first in Zhejiang Province), Zhejiang outstanding private enterprises, innovative enterprises in Zhejiang Province, Jinhua Municipal Government Quality Award and other honors.

本文链接: https://brand.waitui.com/e5ade37a5.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

国产创新药里程碑款频获兑现 行业向可持续收益模式转型

国家药监局最新数据显示,2025年我国批准上市的创新药达76个,创历史新高。同时,创新药对外授权交易总金额超过1300亿美元,授权交易数量超过150笔。近期,国产创新药企的里程碑款捷报频传,表明中国创新药研发的价值得到验证。然而,过去由于里程碑款兑现率较低,业内常有“一次性BD”的诟病。如今,随着里程碑款的持续落地,行业正向可持续收益模式转型。(证券时报)

2小时前

多只理财产品业绩比较基准上限下调至不足3%

近期,农银理财、中邮理财、招银理财、上银理财等多家机构下调旗下理财产品业绩比较基准,部分产品最大降幅达100个基点。调整后,多数产品的业绩比较基准上限已不足3%,理财市场低收益新常态特征愈发凸显。受访专家表示,此次调整受市场利率环境变化与监管导向的驱动,后续业绩基准仍面临下行压力,但降幅会逐步收窄。(证券日报)

2小时前

华泰证券:市场或逐步切向业绩修复方向

36氪获悉,华泰证券研报认为,上周A股市场在资金情绪分化下,小盘股涨幅居前,行业轮动持续,向后看,资金面的弹性及后续轮动方向是市场主要关注点。研报认为1月中旬以来,宽基ETF流出金额虽偏高,但考虑到险资等仍有增量、投资者存在套利需求,市场持续放量下,资金侧仍有接力动能。轮动方向或由主题逐步切往存在业绩印证的方向,历史复盘来看,业绩预告披露期内的,景气具备持续修复能力的行业通常具备一定超额收益,具体到本轮,景气修复的线索或主要集中在涨价链、高端制造及AI链中,结合拥挤度进一步考量,配置上可关注电力设备、基础化工、半导体设备等,适度增配周期型红利。

2小时前

国泰君安国际:预期2025年度净利润为12.80亿至13.80亿港元之间,同比上升265%至293%

36氪获悉,国泰君安国际在港交所公告,预期本集团截至2025年12月31日止年度的净利润为12.80亿至13.80亿港元之间,较2024年净利润约3.51亿港元大幅飙升265%至293%。该预期增长的主要原因为本集团企业融资、财富管理、资产管理及交易及投资等核心业务收入全面大幅上升,其中股权融资及经纪业务表现尤为突出。

2小时前

开年迎3家公司上市,北交所总市值逼近万亿元规模

2026年以来,北交所迎来科马材料、爱舍伦、国亮新材三家公司上市,同时还有美德乐、农大科技两家公司进入发行流程。当前北交所正成为服务创新型中小企业的重要阵地。截至1月23日,北交所上市公司达290家,总市值9670.53亿元,逼近万亿元大关。与此同时,北交所IPO审核正保持高频节奏,多家券商认为,在北交所市场制度改革深化背景下,预计后续IPO有望维持高速发行态势。(中证网)

2小时前

本页详细列出关于寿仙谷的品牌信息,含品牌所属公司介绍,寿仙谷所处行业的品牌地位及优势。
咨询